In view of the high response rate with dabrafenib plus trametinib in patients with BRAF V600E‐mutant NSCLC, future research will investigate the position of dabrafenib plus trametinib as an early treatment option compared with platinum‐based chemotherapy or immunotherapy options. Here, BRAF is linked to non-small cell lung carcinoma.